Clinical Trials Browser

INDUSTRY × AZD 6244 × Thoracic × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Phase 1 Active not recruiting

Advanced Non Small Cell Lung Cancer

NCT01933932 2025-11-19

SELECT-1

Phase 3 Active not recruiting

510 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT01750281 2023-10-24

SELECT-2

Phase 2 Completed

212 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT00890825 2018-06-20

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Phase 2 Completed

88 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01809210 2018-03-13

SELECT-3

Phase 1 Completed

55 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Phase 1 Completed

33 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00372788 2014-08-13

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung